Cover Image
QR Code

A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer.

Our objective was to evaluate the tolerability and effect of a daily soy beverage in prostate cancer patients with biochemical failure after radiotherapy. Patients with rising prostate-specific antigen (PSA) after radical radiation for prostate cancer were instructed to consume 500 ml of soy beverag...

Full description

Published in:Nutrition & Cancer Vol. 62; no. 2; pp. 198 - 208
Main Authors: Kwan W, Duncan G, Van Patten C, Liu M, Lim J
Format: research tables/charts Journal Article
Published: Taylor & Francis Ltd Feb/Mar2010
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105295846&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105295846
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01635581
        7MS
      jtl: Nutrition & Cancer
      issn: 01635581
      maglogo: N
    pubinfo:
      dt: Feb/Mar2010
      vid: 62
      iid: 2
      pid: 377
      pub: Taylor & Francis Ltd
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        105295846
        2010539700
        10.1080/01635580903305318
        NLM20099194
        105295846
      ppf: 198
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer.
      aug:
        au:
          Kwan W
          Duncan G
          Van Patten C
          Liu M
          Lim J
        affil: B.C. Cancer Agency: Fraser Valley Centre, Surrey, British Columbia, Canada
      sug:
        subj:
          Cancer Patients Evaluation
          Outcomes (Health Care)
          Prostate-Specific Antigen Analysis
          Prostatic Neoplasms Therapy
          Radiation Therapeutic Use
          Soy Foods Therapeutic Use
          Funding Source
          Human
          Neoplasms Physiopathology
          Nutrition
          Testosterone
          Treatment Duration Evaluation
      ab: Our objective was to evaluate the tolerability and effect of a daily soy beverage in prostate cancer patients with biochemical failure after radiotherapy. Patients with rising prostate-specific antigen (PSA) after radical radiation for prostate cancer were instructed to consume 500 ml of soy beverage daily for 6 mo. Tolerability of the soy beverage and compliance were assessed. PSA doubling times before and after the consumption of soy were compared. Thirty-four subjects were enrolled; 5 withdrew before 1 mo of soy for reasons unrelated to soy consumption. All remaining 29 subjects were included in the analysis. Mean consumption of the assigned soy beverage was 93%. Mild gastrointestinal upset (38%) not affecting soy consumption was the commonest side effect. PSA showed a declining trend in 4 patients (13.8%), and there was a > 100% prolongation of PSA doubling time in 8 patients (27.6%). However, PSA doubling time also showed a 50% or more shortening in 5 patients (17.2%). In our cohort of North American subjects, 6 mo of a daily soy beverage was well tolerated and was associated with a declining trend or more than 2 times prolongation of PSA doubling time in 41% of subjects. Confirmatory studies are warranted.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N